Manufacturer of Controlled Substances Registration: Noramco, Inc., 32324 [2014-12954]

Download as PDF 32324 Federal Register / Vol. 79, No. 107 / Wednesday, June 4, 2014 / Notices Controlled substance Schedule Sufentanil (9740) ......................................................................................................................................................................................... Fentanyl (9801) ........................................................................................................................................................................................... The company plans to manufacture reference standards for distribution to their research and forensics customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized for this registration. No comments or objections have been received. Dated: May 28, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–12952 Filed 6–3–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Manufacturer of Controlled Substances Registration: Noramco, Inc. ACTION: Notice of registration. Noramco, Inc. applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. The DEA grants Noramco, Inc. registration as a manufacturer of those controlled substances. SUPPLEMENTARY INFORMATION: By notice dated December 23, 2013, and published in the Federal Register on January 8, 2014, 79 FR 1390, Noramco, Inc. (GA), 1440 Olympic Drive, Athens, Georgia 30601, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 16:05 Jun 03, 2014 Jkt 232001 systems, verified the company’s compliance with state and local laws, and reviewed the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic or non-narcotic controlled substances listed: Controlled substance Gamma Hydroxybutyric Acid (2010). Dihydromorphine (9145) ............... Morphine-N-oxide (9307) ............. Codeine-N-oxide (9053) ............... Amphetamine (1100) .................... Methylphenidate (1724) ................ Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Opium tincture (9630) .................. Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Carfentanil (9743) ......................... Tapentadol (9780) ........................ Fentanyl (9801) ............................ Schedule I I I I II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. Dated: May 28, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–12954 Filed 6–3–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (OJP) Docket No. 1654] Request for Nominations to the Office of Justice Programs’ Science Advisory Board Office of Justice Programs (OJP), DOJ. ACTION: Notice of Request for Nominations. AGENCY: PO 00000 Frm 00112 Fmt 4703 Sfmt 4703 II II This notice announces that OJP is seeking nominations of individuals to serve on the OJP Science Advisory Board (‘‘Board’’). The Board was established by the Attorney General in 2010. It is chartered to provide OJP, a component of the Department of Justice, with valuable advice in the areas of science and statistics for the purpose of enhancing the overall impact and performance of its programs and activities in criminal and juvenile justice. To this end, the Board currently operates with six (6) subcommittees: National Institute of Justice (NIJ); Bureau of Justice Statistics (BJS); Office of Juvenile Justice and Delinquency Prevention (OJJDP); Bureau of Justice Assistance (BJA); Quality and Protection of Science; and Evidence Translation/ Integration. SUMMARY: Nominations will be accepted through August 29, 2014. DATES: FOR FURTHER INFORMATION CONTACT: Phelan Wyrick, Designated Federal Officer (DFO), Office of the Assistant Attorney General, Office of Justice Programs, 810 7th Street Northwest, Washington, DC 20531; Phone: (202) 353–9254 [Note: this is not a toll-free number]; Email: phelan.wyrick@ usdoj.gov. To make a nomination, please contact Mr. Wyrick (see above for addresses and phone numbers). Nominations should include the name, title, affiliation, and contact information for the nominee. Resumes, statements of interest, and other relevant supporting information are welcome. Self-nominations are welcome. The Board typically meets twice a year to brief the OJP Assistant Attorney General and the Board members on the progress of the subcommittees, discuss any recommendations they may have for consideration by the full SAB, and brief the Board on various OJP-related projects and activities. All meetings of the Board take place in Washington, DC. The Board is a federal advisory committee covered under the Federal Advisory Committee Act, and as such, meetings of the Board are open to the public. Members of the Board include scientists and practitioners with strong backgrounds of applying science in the fields of criminal justice, juvenile justice, or crime victim services. Current SUPPLEMENTARY INFORMATION: E:\FR\FM\04JNN1.SGM 04JNN1

Agencies

[Federal Register Volume 79, Number 107 (Wednesday, June 4, 2014)]
[Notices]
[Page 32324]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-12954]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Noramco, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Noramco, Inc. applied to be registered as a manufacturer of 
certain basic classes of narcotic or non-narcotic controlled 
substances. The DEA grants Noramco, Inc. registration as a manufacturer 
of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated December 23, 2013, and 
published in the Federal Register on January 8, 2014, 79 FR 1390, 
Noramco, Inc. (GA), 1440 Olympic Drive, Athens, Georgia 30601, applied 
to be registered as a manufacturer of certain basic classes of narcotic 
or non-narcotic controlled substances.
    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco, Inc. to manufacture the basic classes of controlled substances 
is consistent with the public interest and with United States 
obligations under international treaties, conventions, or protocols in 
effect on May 1, 1971. The DEA investigated the company's maintenance 
of effective controls against diversion by inspecting and testing the 
company's physical security systems, verified the company's compliance 
with state and local laws, and reviewed the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of the basic classes of narcotic or non-narcotic 
controlled substances listed:

------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Dihydromorphine (9145).....................  I
Morphine-N-oxide (9307)....................  I
Codeine-N-oxide (9053).....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Thebaine (9333)............................  II
Opium tincture (9630)......................  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received.

    Dated: May 28, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-12954 Filed 6-3-14; 8:45 am]
BILLING CODE 4410-09-P